TBK1 and neoplasm: Similarly, we employed Tbk1 siRNA to knockdown TBK1 in vivo (Figure S10A, Supporting Information), and found that ME49Δompdc/gra4 vaccination could not inhibit tumor growth and prolong host survival time when the host Tbk1 was silenced (Figure S10B–D, Supporting Information).